Cancer Research Technology
Log in Register
Menu

T47D/S5 Cell Line

Invented by Dr Anne Lykkesfeldt from Danish Cancer Society
Invented at Danish Cancer Society

Info

Catalogue Number 152111
Antigen/Gene or Protein Targets Oestrogen receptor
Parental Line T47D
Host Human
Tissue Breast
Disease Keywords Breast cancer
Model Tumour line
Relevance The T47D/S5 Cell line is the control for the fulvestrant resistant T47D/182R-1 and T47D/182R-2 cell lines. Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial.
Production Details T47D/S5 cells grows continuously in presence of 5% fetal calf serum.
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions Phenol red free RPMI 1640 + 5% FCS + glutamax + 8µg Insulin/ml
Notes T47DS5 cells express ER alpha and progesterone receptor.

Passage 155 (AL3043, AL3044)
Cellosaurus ID CVCL_1D46

References

There are 8 reference entries for this reagent.

View All References

References: 8 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

Europe PMC ID: 25885472

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Europe PMC ID: 25706943

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Europe PMC ID: 25362855

Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.

Europe PMC ID: 24513268


Add a reference

References: 8 entries

Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.

Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.

SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Thrane et al. 2014. Oncogene. :. PMID: 25362855.

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Kirkegaard et al. 2014. Cancer Lett. 344(1):90-100. PMID: 24513268.

T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant.


Add a reference